Every Form 4 that Immunome, Inc. (IMNM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMNM filings page.
Immunome Inc. director Isaac Barchas reported three open-market sales of common stock totaling 83,464 shares in August 2026. On August 12, he directly sold 11,048 shares at $27.25 per share, leaving 92,211 shares held directly. On August 10 and 11, entities associated with him, including ABHMC II LLC, sold 10,125 and 62,291 shares, respectively; he disclaims beneficial ownership of those shares except for any pecuniary interest. All reported sales occurred automatically under Rule 10b5-1 trading plans adopted on March 31, 2026.
Immunome Inc. director Isaac Barchas reported indirect sales of Immunome common stock executed by AMBHMC II LLC ("ABHMC"), an entity he helps manage. On August 6 and 7, 2026, ABHMC sold a total of 36,088 shares of common stock in open market or private transactions at a weighted average price of $26.06 per share, with price ranges between $26.00 and $26.3318 depending on the trade. These sales occurred automatically under a Rule 10b5-1 trading plan adopted by ABHMC on March 31, 2026. Barchas reports that ABHMC owns the shares and disclaims beneficial ownership except to the extent of any pecuniary interest. A separate line reports 103,259 shares of Immunome common stock held directly by Barchas as of August 6, 2026.
Immunome Inc.’s Chief Business Officer Kinney Horn reported option exercises and related stock sales. On August 4, 2026, Horn exercised employee stock options for an aggregate 90,616 shares of common stock at exercise prices of $12.92 and $10.60 per share, then reported selling 90,616 shares of common stock at a weighted average price of $25.09 per share, within a range of $25.00–$25.295, pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
Immunome Inc.’s Chief Business Officer, Kinney Horn, received equity compensation awards. On July 23, 2026, Horn was granted 31,250 shares of common stock underlying RSUs and 62,500 employee stock options with a $22.01 exercise price, vesting over time subject to continuous service, with options expiring July 22, 2036.
Immunome Inc. reported equity awards to Chief Technical Officer Philip Tsai on July 23, 2026. Tsai received 76,500 stock options at a $22.01 exercise price expiring in 2036 and 38,250 RSUs, all vesting over time contingent on his continuous service, bringing reported direct holdings to 81,550 common shares/RSUs.
Immunome Inc. reported equity awards to its Chief Legal Officer and General Counsel, Sandra G. Stoneman. On July 23, 2026 she received stock options for 76,500 shares at a $22.01 exercise price, expiring July 22, 2036, plus 38,250 RSUs. The RSUs vest 25% annually on each grant-date anniversary, and the options vest 25% on July 23, 2027 with the balance vesting monthly over three years, in each case subject to continued service. Following the RSU award she directly holds 43,805 shares or RSUs of common stock.
Higgins Jack reported acquisition or exercise transactions in this Form 4 filing.
Immunome Inc. granted Chief Scientific Officer Jack Higgins 76,500 employee stock options to buy Common Stock at $22.01 per share, expiring in 2036, and 38,250 RSU-based Common Stock awards on 2026-07-23. Both the options and RSUs vest over time, subject to continuous service, and Higgins also reports indirect custodial holdings of 1,000 shares for each of three children, for which beneficial ownership is disclaimed.
Immunome Inc. Chief Financial Officer Max Rosett received equity awards of 94,500 employee stock options and 47,250 restricted stock units on July 23, 2026.
The options have a $22.01 exercise price, expire July 22, 2036, and vest 25% on July 23, 2027 with the remainder vesting monthly. The RSUs vest 25% annually on each grant anniversary; after the RSU grant he held 101,287 common shares directly and 94,500 options.
Immunome Inc. granted Chief Medical Officer Robert Lechleider 54,000 RSUs and an employee stock option for 108,000 shares at a $22.01 exercise price on 2026-07-23. The RSUs vest 25% annually, while the options vest 25% on July 23, 2027 and monthly thereafter. After these awards he directly holds 69,805 common shares and 108,000 options.
Immunome Inc. granted equity awards to President and CEO Clay B. Siegall on July 23, 2026. He received 180,000 RSUs, with 25% vesting on each anniversary of the grant date, and 360,000 stock options with a $22.01 exercise price, 25% vesting on July 23, 2027 and the remainder in equal monthly installments thereafter, all subject to continued service. Following the RSU grant, he directly holds 870,704 common shares, in addition to the newly granted options.
Immunome Inc. chief business officer Horn Kinney reported an option exercise and share sale. On the same day, Kinney exercised employee stock options to acquire 1,092 shares of common stock at $12.92 per share and sold 1,092 shares at $25.00 per share in an open-market transaction.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following these transactions, Kinney reported no directly held common shares and 128,908 employee stock options remaining, exercisable at $12.92 and expiring on August 8, 2034.
Immunome Inc. director Isaac Barchas reported that an entity associated with him, AMBHMC II LLC, sold a total of 100,000 shares of Immunome common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
The sales occurred on July 6 and July 7, 2026, at weighted average prices of about $24.11 and $24.20 per share across specified price ranges. After these transactions, filings show 108,504 shares held indirectly and 103,259 shares held directly. Barchas disclaims beneficial ownership of the LLC-held shares beyond any pecuniary interest.
Robert Lechleider, Chief Medical Officer of Immunome, exercised stock options for 55,000 shares of common stock at $8.73 per share on July 2, 2026, then sold 55,000 shares in three tranches at weighted average prices of $21.95, $22.76 and $23.44 per share under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following these transactions, he directly holds 15,805 shares of common stock.
Immunome Inc. reported insider sales by entities associated with director Isaac Barchas. On June 30 and July 2, 2026, ABHMC II LLC and Arsenal Bridge Venture II-B LLC completed open‑market sales totaling 201,050 shares of Immunome common stock under pre‑arranged Rule 10b5‑1 trading plans.
The filing shows weighted average sale prices of $21.12, $22.35, and $23.33 across the three reported transactions. After these sales, entities associated with Barchas held 208,504 shares indirectly, while Barchas’s direct holdings were reported at 103,259 shares. He disclaims beneficial ownership beyond any pecuniary interest.
Immunome Inc. Chief Medical Officer Robert Lechleider exercised options and sold shares of common stock. He exercised 55,000 shares at $8.73 per share through an employee stock option, then sold 55,000 shares in open-market transactions at weighted average prices of $19.56 and $20.66.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 26, 2026. After these transactions, he directly holds 15,805 shares of common stock and 345,000 employee stock options, which vest over time and expire on October 26, 2033.
Immunome Inc. Chief Financial Officer Max Rosett reported an exercise-and-sale transaction in company stock. He exercised stock options covering 60,000 shares of common stock at an exercise price of $1.05 per share and, on the same date, sold 60,000 shares of common stock in open-market transactions.
The weighted average sale price was $18.23 per share, with individual trade prices ranging from $17.95 to $18.66. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following the transactions, Rosett directly holds 54,037 shares of Immunome common stock, and the exercised option is now fully vested and fully exercised.
Immunome Inc. director Sandra M. Swain received a grant of stock options covering 9,897 shares of common stock. The options have an exercise price of $18.16 per share and expire on June 9, 2036.
The award vests in four equal quarterly installments starting on June 10, 2026, with additional vesting on the same day of each succeeding fiscal quarter until the one-year anniversary, as long as she continues serving with the company on each vesting date. Following this grant, she holds options for 9,897 shares directly.
Immunome Inc. director Philip Wagenheim received a grant of 9,897 director stock options, each giving the right to buy common stock at an exercise price of $18.16 per share. These options expire on June 9, 2036 and are reported as directly owned.
The option vests in four equal quarterly installments starting on June 10, 2026, with additional vesting dates on the same day of each succeeding fiscal quarter over the following year, conditioned on his continued service with the company at each vesting date.
Immunome Inc. director Jean Jacques Bienaimé received a new stock option grant covering 9,897 shares of common stock. The option has an exercise price of $18.16 per share and expires on June 9, 2036. Following this grant, he holds options for 9,897 shares directly.
The option vests in four equal quarterly installments, beginning on June 10, 2026 and continuing on the same day of each succeeding fiscal quarter for one year, subject to his continued service with the company on each vesting date.
Immunome Inc. reported a Form 4 insider transaction involving stock options linked to director James P. Boylan’s board service. A director stock option covering 9,897 shares of common stock was granted with an exercise price of $18.16 per share and an expiration date of June 9, 2036.
Mr. Boylan has agreed to receive and hold these securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all right, title, and interest in them. The option vests in four equal quarterly installments starting on June 10, 2026, conditioned on his continuous service with the company on each vesting date, and results in a total of 9,897 derivative securities held after the award.
Immunome Inc. director-related entity receives new stock option grant. A director stock option covering 9,897 shares of Immunome common stock was granted at an exercise price of $18.16 per share, expiring on June 9, 2036. The filing lists director Isaac Barchas as reporting person, but he has agreed that any securities granted for his board service are held for the benefit of Arsenal Bridge Ventures, and he disclaims beneficial ownership and all rights in the reported securities.
The option vests in four equal quarterly installments starting on June 10, 2026, through the one-year anniversary, with each vesting date tied to continued service with Immunome. After this award, the reported derivative position in these options is 9,897 units.
Immunome Inc. director Carol Schafer received a grant of stock options as part of her compensation. She was awarded options covering 9,897 shares of common stock at an exercise price of $18.16 per share, expiring on June 9, 2036.
The options vest in four equal quarterly installments starting on June 10, 2026, continuing on the same day of each succeeding fiscal quarter for one year, as long as she remains in continuous service with the company. Following this grant, she directly holds options for 9,897 shares.
Immunome Inc. director Jean Jacques Bienaimé reported offsetting trades in the company’s common stock on June 5, 2026. He made open-market purchases totaling 10,500 shares at prices between $19.27 and $19.48 per share and open-market sales totaling 10,500 shares at prices around $19.41–$19.44 per share, resulting in no net change in shares.
Following these transactions, he directly owned 43,415 shares of Immunome common stock. A footnote states that the sales were matchable with a 1,000‑share purchase under Section 16(b), and he agreed to pay $155 to Immunome, representing the full profit from that short-swing transaction.
Immunome Inc. director Jean Jacques Bienaime bought additional shares of the company’s stock. On May 15, 2026, he made an open-market purchase of 5,000 shares of Immunome common stock at a weighted average price of $20.70 per share.
The filing notes that individual trade prices ranged from $20.645 to $20.72 per share. Following this transaction, Bienaime directly holds 43,415 shares of Immunome common stock, reflecting a modest increase in his personal stake.
Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock at $21.64 per share on April 2, 2026 in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance. Following the sale, Higgins directly holds 22,000 shares of Immunome common stock. He is also listed as custodian for three separate 1,000-share accounts for his children under the Uniform Transfer to Minors Act, but he disclaims beneficial ownership of those custodial shares, which are subject to a lockup agreement dated December 15, 2025.
Immunome Inc. Chief Financial Officer Max Rosett exercised stock options to acquire 71,561 shares of common stock on April 2, 2026, at exercise prices of $1.05 and $1.35 per share. These options were fully vested and had original expiration dates in 2032 and 2033.
On the same day, Rosett sold a total of 65,000 Immunome shares in open-market transactions at weighted average prices of $21.91 and $22.48 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly owned 54,037 shares of Immunome common stock.
Immunome Inc. Chief Scientific Officer Jack Higgins reported a bona fide gift of 6,291 shares of Common Stock. The gift, coded as a disposition, carried a price of $0.00 per share. Following this transfer, he directly holds 31,438 shares of Immunome Common Stock.
The filing also lists indirect holdings of 1,000 shares of Common Stock in each of three custodial accounts for his children, recorded under the Uniform Transfer to Minors Act. Higgins disclaims beneficial ownership of these custodial shares, which are subject to a lockup agreement he entered into on December 15, 2025.
Immunome Inc. President and CEO Clay B. Siegall bought 25,450 shares of Common Stock in an open-market purchase. The transaction occurred on March 27, 2026 at a weighted average price of $19.67 per share, within a price range of $19.63 to $19.70.
Following this purchase, his direct holdings increased to 690,704 shares of Immunome Common Stock.
Immunome Inc. director Philip Wagenheim sold shares of Common Stock in two open-market transactions. He sold 36,800 shares on March 20, 2026 at a weighted average price of $20.47 per share and 28,200 shares on March 23, 2026 at a weighted average price of $20.65 per share. After these sales, he directly owns 341,147 shares of Immunome Common Stock.
Immunome Inc. director Jean Jacques Bienaimé reported open-market purchases of the company’s common stock. On March 10, 2026, he bought 1,000 shares at $22.12 per share, followed by another 1,000 shares at $21.55 per share on March 11, 2026. After these total purchases of 2,000 shares, he directly owns 38,415 shares of Immunome common stock.
Immunome, Inc.'s president and CEO, who is also a director, reported buying additional company stock. On 12/18/2025, the reporting person purchased 46,511 shares of Immunome common stock at a price of $21.5 per share in an open-market style purchase that occurred in connection with the company’s recently completed underwritten public offering of common stock.
Following this transaction, the reporting person beneficially owns 853,247 shares of Immunome common stock held directly. The filing is made on behalf of a single reporting person and reflects a straightforward increase in their direct ownership stake.